Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

SIMPLE SUMMARY: Anti-CD20 treatments produce a prolonged B-cell aplasia that is responsible for a suboptimal humoral response after vaccination against SARS-CoV-2, even months after receiving therapy. However, there is scarce information on the cellular immune response. In this study, we analyzed bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Montserrat, Corona, Magdalena, Rodríguez-Mora, Sara, Casado-Fernández, Guiomar, Zurdo-Castronuño, Alejandro, Mateos, Elena, Ramos-Martín, Fernando, Sánchez-Menéndez, Clara, Murciano-Antón, María Aranzazú, García-Pérez, Javier, Alcamí, José, Pérez-Olmeda, Mayte, Coiras, Mayte, López-Jiménez, Javier, García-Gutiérrez, Valentín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688562/
https://www.ncbi.nlm.nih.gov/pubmed/36428631
http://dx.doi.org/10.3390/cancers14225537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688562/
https://www.ncbi.nlm.nih.gov/pubmed/36428631
http://dx.doi.org/10.3390/cancers14225537

Ejemplares similares